Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential (Journal for ImmunoTherapy of Cancer, 2023)

(untitled) - Derré, L; Lucca, I; Cesson, V; Bohner, P; Crettenand, F; Rodrigues-Dias, S-C; Dartiguenave, F; Masnada, A; Teixeira-Pereira, C; Benmerzoug, S; Chevalier, MF; Domingos-Pereira, S; et al.